LETI-101
Huntington's Disease
PreclinicalActive
Key Facts
About ElevateBio
ElevateBio is a privately-held, revenue-generating biotech company that operates as an integrated technology and manufacturing partner for the cell and gene therapy industry. The company's unique model combines its proprietary Life Edit gene editing platform—featuring one of the world's largest gene editing toolboxes—with the scalable cGMP manufacturing and process development expertise of its BaseCamp business. This dual approach allows ElevateBio to support partners from concept through commercialization while also advancing its own pipeline of genetic medicines. The company has achieved six consecutive years of revenue growth, driven by expansion of its partner-focused services and technology platforms.
View full company profileTherapeutic Areas
Other Huntington's Disease Drugs
| Drug | Company | Phase |
|---|---|---|
| NUZ-001 | Neurizon Therapeutics | Preclinical |
| Huntington's Disease Program | Rumi Scientific | Pre-clinical |
| SOM3355 | SOM Biotech | Phase 3 |
| Somatic Expansion Inhibitor Program | LoQus23 Therapeutics | Preclinical |
| Preclinical Program | Excision BioTherapeutics | Preclinical |
| NA-841 | Biomed | Phase 2A |
| T3D-959 (Future) | T3D Therapeutics | Pre-clinical / Research |
| HD mAb Therapy | HD Immune | Pre-clinical |
| TT-P34 | Teitur Trophics | Pre-clinical |
| INT41 | Vybion | Pre-clinical |
| Huntington's Program | reMYND | Pre-clinical |
| Pridopidine | Prilenia Therapeutics | Phase 3 |